Related Experiment Video

Updated: May 23, 2026

Chromosome Preparation From Cultured Cells
07:42

Chromosome Preparation From Cultured Cells

Published on: January 28, 2014

The clinical relevance of chromosomal and genomic abnormalities in B-cell precursor acute lymphoblastic leukaemia

Anthony V Moorman1

  • 1Leukaemia Research Cytogenetics Group, Northern Institute for Cancer Research, Newcastle University, United Kingdom. anthony.moorman@newcastle.ac.uk

Blood Reviews
|March 23, 2012
PubMed

Insights

Childhood acute lymphoblastic leukaemia (ALL) has high cure rates, but adult ALL survival is poor. Genetic abnormalities are key to understanding ALL biology, prognosis, and improving patient outcomes.

Area of Science:

  • Genetics
  • Oncology
  • Paediatrics

Background:

  • Acute lymphoblastic leukaemia (ALL) is the most common childhood cancer, with high cure rates.
  • Adult ALL survival rates are significantly lower than in children.
  • Genetic abnormalities are crucial for understanding ALL biology and patient prognosis.

Purpose of the Study:

  • To review genetic abnormalities used in managing B-cell precursor ALL.
  • To discuss evidence for newly identified genomic abnormalities in ALL.

Main Methods:

  • Literature review of genetic abnormalities in acute lymphoblastic leukaemia.
  • Analysis of prognostic and predictive markers in ALL patient cohorts.
  • Discussion of current and emerging genomic findings.

Main Results:

  • A wide spectrum of chromosomal and genomic abnormalities are associated with ALL patient outcomes.
  • Only a subset of these genetic aberrations are currently utilized for patient risk stratification.
  • Advances in technology continually expand the known landscape of ALL genetic alterations.

Conclusions:

  • Genetic markers are vital for improving ALL patient management and outcomes.
  • Continued research into novel genomic abnormalities is essential for advancing ALL treatment strategies.

More Related Videos

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation09:02

Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation

Published on: November 26, 2018

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia10:18

From a 2DE-Gel Spot to Protein Function: Lesson Learned From HS1 in Chronic Lymphocytic Leukemia

Published on: October 19, 2014

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...